Stock report · Delisted · Nasdaq
Theratechnologies Inc. (THTX)
3.39USD Delisted Final close · Sep 24, 2025
THTX no longer trades. Theratechnologies was delisted from the Nasdaq in September 2025.
All prices on this page are historical. The last trade was on September 24, 2025, at $3.39.
THTX stock price history
Final trading statistics
- Final close
- $3.39
- Final trading day
- Sep 24, 2025
- Market cap at delisting
- $155.87M
- Shares outstanding
- 45.98M
- Final 52-week range
- $1.12 – $3.39
- Avg. volume (final 3 mo.)
- 653,735
- All-time high
- $44.96 · May 2018
- All-time low
- $0.72 · Sep 2013
- Return since IPO
- -20.0%
- Beta
- 0.81
- Book value / share
- −$0.61
- Price / book
- -5.58
About Theratechnologies Inc.
Theratechnologies Inc. was a biopharmaceutical company selling therapies for unmet medical needs in the United States, Canada and Europe. EGRIFTA SV reduced excess belly fat in HIV patients with lipodystrophy, and Trogarzo treated multidrug-resistant HIV-1 in heavily treated adults whose current regimen was failing.
Its pipeline included tesamorelin F8, in Phase 2 for nonalcoholic steatohepatitis; SORT1+ Technology, a Phase 1 peptide platform for cancer drugs aimed at SORT1 receptors; and sudocetaxel zendusortide, in Phase 1 for several solid tumors including breast, ovarian, endometrial, melanoma, thyroid, small cell lung and prostate cancers.
It also sold olezarsen, an RNA-targeted drug for familial chylomicronemia syndrome and severe hypertriglyceridemia, and donidalorsen for attacks of hereditary angioedema. Incorporated in 1993 and based in Montreal, it became a subsidiary of CB Biotechnology, LLC as of September 25, 2025. Its stock was delisted from the Nasdaq that month, with a final trade on September 24, 2025 at $3.39.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Montreal, QC
- Employees
- —
- IPO date
- January 4, 2016
- Delisted
- September 24, 2025
- SEC CIK
- 1512717
Theratechnologies financials before the delisting
The last 5 fiscal years Theratechnologies reported as a public company, fiscal year ending November.
THTX revenue and net income
THTX earnings per share
THTX annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $85.87M | −$8.3M | −$0.25 |
| FY2023 | $81.76M | −$24.0M | −$0.66 |
| FY2022 | $80.06M | −$47.2M | −$0.50 |
| FY2021 | $69.82M | −$31.7M | −$0.34 |
| FY2020 | $66.05M | −$22.7M | −$0.29 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Theratechnologies stock FAQ
What happened to Theratechnologies stock?
Theratechnologies was delisted from the Nasdaq in September 2025. The final close was $3.39 on September 24, 2025.
Can I still buy THTX stock?
No. THTX is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on September 24, 2025.
What was the last price of THTX?
THTX last closed at $3.39 on September 24, 2025, which valued the company at about $155.87M.
How did Theratechnologies do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Theratechnologies reported revenue of $85.87M and net income of −$8.3M.
When did Theratechnologies go public?
Theratechnologies shares started trading on January 4, 2016.
THTX no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.